ATAI Life Sciences Stock (NASDAQ:ATAI), Trade Ideas

ATAI Life Sciences

ATAI Life Sciences NV is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders. Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01/Salvinorin A, KUR-101/Deuterated Mitragynine, and DMX-1001/Noribogaine. The business operates geographically in two regions being the United States and Germany.

Jim Cramer Photo by s_bukley on Shutterstock

General

ATAI

CMPS

MNMD

Jim Cramer Slams Political Blocking Of &#39;LSD-Derived Antidepressants,&#39; Citing Strong Test Data &#39;Showing They Worked&#39;

Psyched

Biotech

Cannabis

Psychedelics

AGNPF

CMND

DRUG

ENVB

GHRS

IXHL

LSDI

OPTHF

PSIL

SILO

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna &amp; More

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

ABAT

ABIO

ACOR

ADXN

ANGH

APLD

BCAN

BROG

CALM

CASA

CETY

CISS

CRML

CXAI

DXYZ

EGOX

ESPR

EXAI

FGEN

GCTS

GMDA

INTC

Kintara Therapeutics, Inc. - Common Stock

KTRA

KYCH

LCFY

LGVC

MESO

MRNO

NWTN

Next Technology Holding Inc. - Ordinary Shares

NXTT

ONMD

PLAY

PYXS

SINT

SMTC

TCON

ULTA

VIEW

VNDA

VVPR

XTIA

Shares of  Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company&#39;s presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook.

Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday.

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday&#39;s Mid-Day Session

ATAI Life Sciences NV

Atai Life Sciences Disclosed Dosing Of First Patient In Part 2 Of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive To SSRIs In Patients With Treatment Resistant Depression

Jim Cramer recently hyped up one of his guests in advance of his CNBC show "Mad Money," posting on X that people "will be very interested in MindMed for certain &#8230; LSD," and he made sure his interview did not disappoint.
Mind Medicine Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) sees a massive market opportunity ahead, citing 21% of U.S. adults with an anxiety disorder, an estimated 4.4% of U.S. adults with attention-deficit/hyperactivity disorder (ADHD) and a $461 billion economic cost from autism spectrum disorder by 2025.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/zette">Anyone can invest in this Harvard-founded AI startup</a> solving paywalls and growing 5x yearly by partnering with Forbes, Daily News and more.</li>
<li>Invest alongside execs from Uber, Facebook and Apple in this<a href="https://www.benzinga.com/money/aura"> wellness app Transforming a $5.6 TRILLION dollar industry</a>.</li>
</ul>
While the conditions they're seeking to treat are not new, MindMed's plan to treat patients with LSD and MDMA-derived therapies could be described as unconventional.
But its story has gained investors' attention. MindMed shares have had an impressive run this year, with its stock up over 167% year to date.
One reason for the stock's recent jump was the Food and Drug Administration's (FDA) decision to grant breakthrough designation for MindMed's LSD-based treatment for generalized anxiety disorder.
<a href="https://www.benzinga.com/topic/mindmed">MindMed</a> Chief Medical Officer Dr. Daniel Karlin described the achievement, saying, "A breakthrough designation is a recognition that a drug has demonstrated evidence of clinical efficacy in meeting an unmet medical need" and called it "an offer from the agency to engage more closely in drug development."
Trending: Invest like a millionaire. Exclusive opportunity to<a href="https://www.benzinga.com/money/epic-games"> invest in Epic Games $17 billion gaming empire.</a>
Following the interview, Cramer suggested that scientific advances in psychedelics-based therapy are taking a backseat to political agendas, posting on X that "<a href="https://t.co/OfcgQY7TtX">Mindmed.com</a> intrigued me because it is pretty clear that the LSD-derived antidepressants were blocked politically and criminalized after good tests showing they worked!!!"
MindMed reported results from its phase IIB trial of its MM-120 drug, an LSD-derived therapy, which showed a 78% clinical response against anxiety versus just 31% for a placebo.
Only "transient mild-to-moderate" adverse effects were reported, with none of the study's participants in even the highest trial doses stopping the trial because of side effects.
"These promising findings represent a major step forward in our goal to bring a paradigm-shifting treatment to the millions of patients who are profoundly impacted by GAD [generalized anxiety disorder]," MindMed CEO Robert Barrow said.&nbsp;
MindMed's shares still have a long way to go to get back to its 2021 peak, with the stock down nearly 84% since then.
The stocks of other companies developing psychedelic-derived therapies, such as ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) and Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>), also remain well off their peaks.
Keep Reading <a href="https://www.benzinga.com/alternative-investments/startups">About Startups</a>:
<ul>
<li>This startup coined &#8220;eBay for gamers&#8221; with a breathtaking track record has opened up<a href="https://www.benzinga.com/money/gameflip-2"> a window to invest in its future growth</a>.</li>
<li>Join the elite. Invest in Epic Games and<a href="https://www.benzinga.com/money/epic-games"> own a piece of the $17 billion Fortnite empire</a>.</li>
</ul>

Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked'

<h3 class="wp-block-heading">DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings</h3>
The Drug Enforcement Administration (DEA) is revisiting its stance on the classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC).&nbsp;&nbsp;
The agency has proposed both be listed as Schedule I substances under the Controlled Substances Act (CSA). If added to the Schedule I list, these compounds would be officially considered as having high abuse potential with no recognized medical use.
The evaluation is being disputed by experts. Three formal requests for a hearing were submitted, prompting a reconsideration by the agency. The listing raises concerns within the scientific community and companies developing neurological and medical research that rely on them. <a href="https://www.benzinga.com/government/24/04/38053487/dea-revisits-proposed-ban-on-two-psychedelic-compounds-researchers-disagree-insist-on-hearings">Learn more</a>.
<h3 class="wp-block-heading">Russell Newcombe Dies &#8211; Legacy Of UK&#8217;s Longtime Harm Reduction Advocate, Committed Drug Researcher</h3>
April 4 was a sad day for the drug research and harm reduction advocate communities worldwide with the news of Russell Newcombe's passing. A prominent figure in the field of harm reduction, the English psychologist and researcher played an active role in informing and advocating for harm reduction strategies on a global scale.
Researcher, lecturer, trainer and consultant on drug use and drug policy for some 40 years at various institutions and organizations across the globe, his main areas of interest included the psychosocial effects of drugs, reduction of drug-related risks and harms, discrimination against people drug user, scientific evaluation of drug strategies and drug services and novel psychoactive substances. <a href="https://www.benzinga.com/markets/cannabis/24/04/38119247/russell-newcombe-dies-legacy-of-uks-longtime-harm-reduction-advocate-committed-drug-researcher">Keep reading</a>.
<h3 class="wp-block-heading">Podcast: Expert Talks About &#8216;Kanna,&#8217; The Legal African Succulent That Elevates Awareness, Concentration And More</h3>
Welcome to a new episode of the Benzinga Psychedelics Podcast where we&#8217;re joined by Stephanie Wang, founder of business KA! Empathogenics and speaker about alternative mental health, emotional wellness, resilience-building in the nervous system and connection to self, others and nature through the lens of plant medicine.
KA! focuses on bringing to market products that contain the ancient healing plant kanna, paired with modern science, for an alternative, legal means to help people with mental health issues. Kanna is legal in the U.S., unlike most psychoactive substances.
<a href="https://www.benzinga.com/markets/cannabis/24/04/38222050/podcast-expert-talks-about-kanna-the-legal-african-succulent-that-elevates-awareness-concentrati">Find out more</a> and <a href="https://open.spotify.com/episode/433Z5oT9IwOkbJpQ4TXQXs?si=d8a4a6e8555d4050">listen here</a>.
<h3 class="wp-block-heading">The Milestone Round</h3>
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/03/38004616/atai-life-sciences-q4-and-full-year-2023-results-steep-cash-drain-yet-2026-target-remains-update-">Atai Life Sciences</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) shared its Q4 and full-year 2023 results.</li>
<li><a href="https://www.benzinga.com/general/biotech/24/04/38079502/dmt-for-stroke-treatment-algernon-sets-phase-2-clinical-trial-design">DMT for stroke treatment</a>: Algernon Pharmaceuticals (OTC:<a class="ticker" href="https://www.benzinga.com/stock/AGNPF#OTC">AGNPF</a>) sets its Phase 2 clinical trial design.</li>
<li>Optimi Health (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OPTHF#OTC">OPTHF</a>) will supply <a href="https://www.benzinga.com/markets/cannabis/24/04/38171058/optimi-to-supply-psilocybin-for-new-zealands-m-tai-medical-research-institute">psilocybin for New Zealand&#8217;s Mātai</a> Medical Research Institute.</li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/04/38113294/psychedelics-reform-update-missouris-10m-budget-maines-marylands-study-groups-oregons-re-crim-an">Psychedelics reform update</a>: Missouri&#8217;s $10 million budget, Maine&#8217;s &amp; Maryland&#8217;s study groups, Oregon&#8217;s re-crim and more.</li>
</ul>
See Also: <a href="https://www.benzinga.com/general/biotech/24/03/38007276/psyched-5-meo-dmt-for-depression-utah-hospitals-providing-therapy-elon-musk-and-metas-influence">Prior Edition Of ‘Psyched'</a>
<h3 class="wp-block-heading">Psychedelics ETF&#8217;s Weekly Performance</h3>
AdvisorShares Psychedelics ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSIL#NYSE">PSIL</a>) opened Monday, April 15 at $1.38, following openings at $ 1.51, $1.46 and $1.45 (April 8, April 1 and March 25 respectively.)
On Friday, April 12 it closed at $1.37, following prior closings at $1.49, $1.49 and $1.44 (April 5, March 28 and March 22, respectively.)
The week&#8217;s highest within open market hours was $1.51, vs. prior highest points at $1.56, $1.49 and $1.55.
Week&#8217;s lowest (open market hours) was $1.37 vs. prior lowest points at $1.43, $1.42 and $1.41.&nbsp;
<h3 class="wp-block-heading">Highest Trading Psychedelics Stocks Thursday, April 12 Close</h3>
<ul>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) closed at $11.19, following prior closings at $11.13, $10.66 and $10.54 (April 5, March 28 and March 22.)</li>
<li>Mind Medicine (MindMed) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) closed at $9.76, following prior closings at $10.99, $9.53 and $9.85.&nbsp;</li>
<li>COMPASS Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) closed at $8.88, following prior closings at $9.50, $8.33 and $8.99.</li>
<li>Incannex Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) closed at $2.97, following prior closings at $3.25, $3.60 and $2.82.&nbsp;&nbsp;</li>
<li>Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) closed at $2.30, following prior closings at $2.43, $1.93 and $1.63.</li>
<li>Silo Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) closed at $1.97, following prior closings at $2.05, $1.92 and $1.86.</li>
<li>Bright Minds Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) closed at $1.27, following prior closings at $1.25, $1.20 and $1.22.&nbsp;</li>
<li>Clearmind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) closed at $1.25, following prior closings at $1.15, $1.15 and $1.18.&nbsp;</li>
<li>Lucy Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) closed at $1.24, following prior closings at $1.28, $1.39 and $1.38.&nbsp;</li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) closed at $1.00, following prior closings at $0.97, $1.03 and $1.13.</li>
</ul>
Stock trading numbers above according to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, our all-the-information-you-need streaming platform helping you invest smarter – Come join us and see for yourself!

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More

<a href="https://www.globenewswire.com/Tracker?data=lOoXgliIVUq_pb3hmgJD7im-dM0D5NV9Dhb5ylZLgMIVbO7vVxmZIb3CwJEdzBNDIH8itS5NxZJmmM2JenV1d9C4x2FEvCCl8CrGxfKpwTYufrnPxXayDm68dmXvzbyjmmOBtjrl8HVFs_q0eeUxUdDZUWJKRMitOkjKrAcvrR-01elTaPGdmZXMAi6C_yIK4jpoi_nBY6y0CgJrCetD29cc8ziYQXv6DCjFhejObFoDXwNc_LyJ07iZvic7zUafbgrMeRDgRkCvtd8k9EJInldeU0cGMMbcgqIntuYgHlsX_glWlTyg-pbOWlPTUCVSGSTT8TwfprkddvBIrNC8MXWS7gckzIGQq_7tvwpktL9_4FwVpF4Xe1Mtz-0gtVNLhRJcw0xDiDtcEnk85lWd3UXi-AmeoF93RYQBiMbGwzQA5hhFYzoanACl454L2A1O" target="_blank">atai Life Sciences</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) (&quot;atai&quot; or &quot;Company&quot;), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech&#39;s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in&nbsp;The Journal of Psychopharmacology.
The double-blind, placebo-controlled, single ascending dose Phase 1 study explored the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BPL-003 in combination with psychological support in 44 psychedelic-na&iuml;ve healthy volunteers. Participants across seven cohorts were given either a single dose of BPL-003 between 1 mg to 12 mg or a placebo.

ATAI Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

Cantor Fitzgerald analyst Charles Duncan reiterates ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Overweight.

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on ATAI Life Sciences

Shares of Ulta Beauty, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ulta#NASDAQ">ULTA</a>) fell sharply during Wednesday&rsquo;s session amid the company&#39;s presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook.
Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>ARCA biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abio#NASDAQ">ABIO</a>) climbed 108% to $3.5549 after the company and Oruka Therapeutics announced a merger agreement.</li>
<li>Kintara Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ktra#NASDAQ">KTRA</a>) shares gained 89% to $0.1906 after the company entered a merger agreement with TuHURA Biosciences.</li>
<li>Next Technology Holding Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxtt#NASDAQ">NXTT</a>) rose 57.4% to $6.42.</li>
<li>Vanda Pharmaceuticals Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vnda#NASDAQ">VNDA</a>) shares climbed 39.3% to $5.45. Vanda Pharmaceuticals&#39; Fanapt&reg; received U.S. FDA approval for the acute treatment of Bipolar I Disorder.</li>
<li>VivoPower International PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vvpr#NASDAQ">VVPR</a>) shares gained 39% to $8.20 after the company declared a capital management strategy including a stock buyback program of up to $5 million.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) gained 32.7% to $0.0345.</li>
<li>XTI Aerospace, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xtia#NASDAQ">XTIA</a>) rose 32.2% to $4.63. BestGrowthStocks.com issued comprehensive evaluation of XTI Aerospace, Inc.</li>
<li>Brooge Energy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brog#NASDAQ">BROG</a>) gained 28.8% to $3.0790.</li>
<li>Addex Therapeutics Ltd (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adxn#NASDAQ">ADXN</a>) rose 24.6% to $16.21 after the company and funds affiliated with Perceptive Advisors announced the launch of Neurosterix.</li>
<li>Aesthetic Medical International Holdings Group Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aih#NASDAQ">AIH</a>) gained 24.3% to $0.3981 after gaining 13% on Tuesday.</li>
<li>LAMF Global Ventures Corp. I (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lgvc#NASDAQ">LGVC</a>) gained 22.7% to $13.21. ViewLAMF Global Ventures Corp. I shareholders approved previously announced business combination with Nuvo Group Ltd.</li>
<li>Quhuo Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/qh#NASDAQ">QH</a>) rose 21.7% to $0.6501 after reporting unaudited financial results for the second half and full year 2023.</li>
<li>Destiny Tech100 Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NYSE">DXYZ</a>) gained 21.4% to $25.77.</li>
<li>OneMedNet Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/onmd#NASDAQ">ONMD</a>) gained 21.2% to $0.9600. OneMedNet announced it entered a securities purchase agreement dated Mar. 28 providing up to $4.54 million in funding through private placement of senior convertible notes.</li>
<li>CXApp Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cxai#NASDAQ">CXAI</a>) gained 20.5% to $5.40 following a massive rally to start the week. CXApp shares rallied more than 150% to start the week after the company announced a partnership with Alphabet&rsquo;s Google Cloud.</li>
<li>Clean Energy Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cety#NASDAQ">CETY</a>) climbed 20.5% to $1.63.</li>
<li>American Battery Technology Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abat#NASDAQ">ABAT</a>) rose 17.7% to $1.9301. American Battery Technology Company was awarded $20 million tax credit through competitive U.S. DOE process to advance its critical minerals battery recycling facility.</li>
<li>C3is Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ciss#NASDAQ">CISS</a>) shares rose 14.9% to $0.0470 after gaining 13% on Tuesday. On March 26, C3is reported a year-over-year increase in fourth-quarter financial results.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) gained 12.3% to $6.04.</li>
<li>Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) surged 11.4% to $2.08. Maxim Group analyst Jason McCarthy upgraded ATAI Life Sciences from Hold to Buy and announced a $6 price target.</li>
<li>Dave &amp; Buster&#39;s Entertainment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/play#NASDAQ">PLAY</a>) shares rose 10.2% to $68.22 after the company reported fourth quarter results.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) jumped 9.7% to $3.16.</li>
<li>Signet Jewelers Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sig#NYSE">SIG</a>) gained 9.2% to $103.80after the company raised its FY25 guidance.</li>
<li>Inspire Veterinary Partners, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ivp#NASDAQ">IVP</a>) gained 9% to $0.0512. On Jan. 5, Inspire Veterinary Partners filed a prospectus related to up to a $5 million public offering.</li>
<li>Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) gained 7.4% to $30.28.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) climbed 6.8% to $62.88 after the company reported upbeat results for its fourth quarter.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Casa Systems, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/casa#NASDAQ">CASA</a>) shares dipped 78.1% to $0.0563 after the Company filed voluntary petitions for relief under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court.</li>
<li>View, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/view#NASDAQ">VIEW</a>) fell 61.9% to $0.4196 after the company filed for Chapter 11 bankruptcy. The company on Tuesday said it reached a real with Cantor Fitzgerald and RXR to become a private company.</li>
<li>Sintx Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sint#NASDAQ">SINT</a>) fell 44.5% to $0.0232 after the company announced pricing of a $1.5 million public offering of common stock.</li>
<li>GCT Semiconductor Holding, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gcts#NYSE">GCTS</a>) dipped 40% to $9.29 amid volatility following the company&#39;s recently completed business combination with Concord Acquisition Corp III and NYSE debut.</li>
<li>FibroGen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/fgen#NASDAQ">FGEN</a>) fell 32.8% to $1.4499. FibroGen announced topline data from the Fortis Therapeutics-sponsored Phase 1 study of FG-3246 (also known as FOR46), a potential first-in-class anti-CD46 antibody drug conjugate (ADC) with an MMAE-containing payload.</li>
<li>Keyarch Acquisition Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/kych#NASDAQ">KYCH</a>) fell 28.5% to $9.65.</li>
<li>TRACON Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tcon#NASDAQ">TCON</a>) dipped 24.2% to $0.3148 as the company issued an update on ongoing ENVASARC Phase 2 pivotal trial following Independent Data Monitoring Committee Recommendation to continue the trial as planned.</li>
<li>BYND Cannasoft Enterprises Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcan#NASDAQ">BCAN</a>) fell 22.5% to $0.9741 after dipping around 12% on Tuesday.</li>
<li>Anghami Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/angh#NASDAQ">ANGH</a>) fell 22.2% to $1.40. Anghami recently announced that it completed its transaction with OSN+.</li>
<li>Locafy Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lcfy#NASDAQ">LCFY</a>) dipped 21.9% to $3.67 following second-quarter results.</li>
<li>Vicinity Motor Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vev#NASDAQ">VEV</a>) fell 19.3% to $0.75 after the company reported a year-over-year decrease in fourth-quarter EPS results.</li>
<li>Enveric Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/envb#NASDAQ">ENVB</a>) dipped 18.4% to $0.93.</li>
<li>Murano Global Investments Plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) fell 16.8% to $10.39.</li>
<li>Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 16.7% to $11.66.</li>
<li>Acorda Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acor#NASDAQ">ACOR</a>) shares fell 12% to $2.20. Acorda Therapeutics shares dipped 81% on Tuesday after the company commenced voluntary proceedings under Chapter 11 of the United States Bankruptcy Code.</li>
<li>Exscientia plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/exai#NASDAQ">EXAI</a>) fell 10.8% to $4.6395 following quarterly results.</li>
<li>Gamida Cell Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gmda#NASDAQ">GMDA</a>) shares fell 8.4% to $0.0403 after gaining 18% on Tuesday.</li>
<li>e.l.f. Beauty, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/elf#NYSE">ELF</a>) fell 8.2% to $170.71 after peer Ulta Beauty reportedly issued weak guidance at a conference.</li>
<li>NWTN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nwtn#NASDAQ">NWTN</a>) fell 8% to $7.21.</li>
<li>Mesoblast Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/meso#NASDAQ">MESO</a>) shares tumbled 7.3% to $6.11 after gaining 8% on Tuesday.</li>
<li>Applied Digital Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/apld#NASDAQ">APLD</a>) fell 6.1% to $3.5850.</li>
<li>Lands&#39; End, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/le#NASDAQ">LE</a>) fell 6.1% to $11.25.</li>
<li>Intel Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/intc#NASDAQ">INTC</a>) fell 6.1% to $41.27 after the company outlined a new financial framework for its foundry business. After the market close on Tuesday, Intel announced a new financial reporting structure designed to drive increased cost discipline and higher returns by providing greater transparency, accountability and incentives across the business.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38069445/ethereum-trades-below-3-400-following-adp-report-stacks-becomes-top-loser"> Ethereum Trades Below $3,400 Following ADP Report; Stacks Becomes Top Loser</a>

Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session

WIIM

ATAI Life Sciences shares are trading higher after Maxim Group upgraded the stock from Hold to Buy and announced a $6 price target.

U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday.
Shares of Signet Jewelers Limited (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sig#NYSE">SIG</a>) rose sharply during Wednesday&rsquo;s session after the company <a href="https://www.benzinga.com/markets/equities/24/04/38068195/whats-going-on-with-signet-jewelers-stock-today">raised its FY25 guidance.</a>
The company and Leonard Green &amp; Partners, L.P., an equity investment firm, today announced the amendment of the terms of the Series A Convertible Preference Shares to net share settlement and the repurchase of half of the Preferred Shares. 
Signet increased its FY25 adjusted EPS outlook to $9.90 &ndash; $11.52 from $9.08 &ndash; $10.48 versus an estimate of $9.72.
Signet Jewelers shares surged 9.2% to $103.80 on Wednesday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>Destiny Tech100 Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dxyz#NYSE">DXYZ</a>) shares jumped 21.4% to $25.77.</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) shares gained 14.2% to $1.5750. HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterated Ocugen with a Buy and maintained a $7 price target.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) rose 12.3% to $6.04.</li>
<li>Atai Life Sciences N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/atai#NASDAQ">ATAI</a>) climbed 11.4% to $2.08. Maxim Group analyst Jason McCarthy upgraded ATAI Life Sciences from Hold to Buy and announced a $6 price target.</li>
<li>SolarMax Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smxt#NASDAQ">SMXT</a>) rose 10.4% to $11.85.</li>
<li>Dave &amp; Buster&#39;s Entertainment, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/play#NASDAQ">PLAY</a>) shares gained 10.2% to $68.22 after the company reported fourth quarter results.</li>
<li>Esperion Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/espr#NASDAQ">ESPR</a>) gained 9.7% to $3.16.</li>
<li>TransMedics Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tmdx#NASDAQ">TMDX</a>) rose 9.2% to $79.47.</li>
<li>Porch Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prch#NASDAQ">PRCH</a>) gained 8.3% to $4.3450. Cantor Fitzgerald analyst Josh Siegler maintained Porch Group with an Overweight and raised the price target from $3 to $5.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/zim#NYSE">ZIM</a>) gained 7.7% to $10.95.</li>
<li>Semtech Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/smtc#NASDAQ">SMTC</a>) climbed 7.4% to $30.28.</li>
<li>Cal-Maine Foods, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/calm#NASDAQ">CALM</a>) shares gained 6.8% to $62.88 after the company reported upbeat results for its fourth quarter.</li>
<li>Glaukos Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gkos#NYSE">GKOS</a>) rose 6.8% to $95.59. Glaukos received permanent J-code for iDose&reg; TR (travoprost intracameral implant).</li>
<li>Blue Owl Capital Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/owl#NYSE">OWL</a>) gained 6.4% to $19.69 after the company announced a purchase agreement to acquire Kuvare Insurance Services LP for $750 million.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) rose 6.3% to $23.88.</li>
<li>U.S. Silica Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/slca#NYSE">SLCA</a>) gained 6.2% to $13.47.</li>
<li>Spotify Technology S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/spot#NYSE">SPOT</a>) rose 5.6% to $284.61 on reports the company will raise monthly prices.</li>
<li>Arcadium Lithium plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/altm#NASDAQ">ALTM</a>) gained 4.8% to $4.34. Raymond James upgraded the stock from Outperform to Strong Buy and maintained its $9 price target.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/04/38062892/how-to-earn-500-a-month-from-levi-strauss-stock-ahead-of-q1-earnings-report"> How To Earn $500 A Month From Levi Strauss Stock Ahead Of Q1 Earnings Report</a>

ALTM

GKOS

OCGN

PRCH

RILY

SLCA

SMXT

SPOT

TMDX

Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday

Maxim Group analyst Jason McCarthy upgrades ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) from Hold to Buy and announces $6 price target.

Upgrades

Price Target

Maxim Group Upgrades ATAI Life Sciences to Buy, Announces $6 Price Target

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and lowers the price target from $20 to $15.

HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Lowers Price Target to $15

<h3 class="wp-block-heading">Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression</h3>
Partners Beckley Psytech and atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) have jointly announced positive initial results from a Phase 2a study of Beckley&#8217;s novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.) 
BPL-003 is a synthetic and patent-protected benzoate salt formulation of 5-MeO-DMT (aka mebufotenin) designed for intranasal administration. The open-label study assessed safety, tolerability and efficacy of the compound at a single 10mg dose, alongside psychological support, in patients with moderate-to-severe TRD (who withdrew from concomitant antidepressants.) <a href="https://www.benzinga.com/general/biotech/24/03/37994428/intranasal-5-meo-dmt-clinical-trial-offers-hope-for-treatment-resistant-depression">Learn more</a>.
<h3 class="wp-block-heading">Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions</h3>
Providers at Utah&#8217;s two largest healthcare systems may now treat patients with psilocybin and MDMA as part of a pilot program created by a proposal-turned-law that will take effect as early as May 1, 2024. 
The program, open to providers at the University of Utah Health and Intermountain Health, will last three years. Next, the Legislature will decide whether or not to resume it. <a href="https://www.benzinga.com/markets/cannabis/24/03/37925833/utah-hospitals-will-soon-provide-psilocybin-and-mdma-therapy-for-mental-health-conditions">Learn more</a>.
<h3 class="wp-block-heading">Elon Musk On Ketamine And Investors&#8217; Value: &#8216;If There Is Something I&#8217;m Taking, I Should Keep Taking It&#8217;</h3>
Elon Musk once again made the case for using psychedelics. In a new interview with former CNN anchor Don Lemon, the business magnate said prescription ketamine has helped him with occasional depressive episodes. He also suggested that taking the ketamine has also been beneficial for investors in his companies.
The Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and SpaceX chief executive says he takes &#8220;a small amount once every other week,&#8221; and sometimes less frequently, to treat the &#8220;chemical tides&#8221; that can trigger his depression. &#8220;Ketamine is helpful for getting one out of a negative frame of mind,&#8221; Musk told Lemon. <a href="https://www.benzinga.com/general/biotech/24/03/37797951/elon-musk-on-ketamine-and-investors-value-if-there-is-something-im-taking-i-should-keep-taking-it">Keep reading</a>.
<h3 class="wp-block-heading">Do Meta And Other Platforms Play A Role In Illicit Drug Sales? US Prosecutors Intend To Find Out</h3>
Prosecutors in Virginia are probing whether Facebook-parent Meta&#8217;s social media platforms Facebook and Instagram are facilitating and profiting from the illegal sale of drugs, according to a Saturday <a href="https://www.wsj.com/tech/u-s-is-investigating-meta-for-role-in-drug-sales-574944cb">Wall Street Journal report</a>.
Led by Assistant U.S. Attorney Randy Ramseyer, the investigation includes delving into whether Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) failed to adequately remove drug-related content from its platforms. <a href="https://www.benzinga.com/markets/cannabis/24/03/37767225/do-meta-and-other-platforms-play-a-role-in-illicit-drug-sales-us-prosecutors-are-investigating">Read more</a>.
<h3 class="wp-block-heading">Podcast: LSD &#8216;Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics&#8217; Says MindMed&#8217;s R. Barrow</h3>
Welcome to a new episode of the Benzinga Psychedelics Podcast where we're joined by Robert Barrow, CEO of Mind Medicine (MindMed) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>), which has taken the development of LSD-based therapy to new heights. The biopharma company recently obtained a &#8220;breakthrough therapy&#8221; designation for the <a href="https://www.benzinga.com/general/biotech/24/03/37542756/mindmed-receives-fda-breakthrough-therapy-designation-for-lsd-as-anxiety-treatment-shares-positiv">treatment of generalized anxiety</a> from the U.S. Food and Drug Administration (FDA.) 
<a href="https://www.benzinga.com/general/biotech/24/03/37960454/podcast-lsd-deserves-to-reclaim-its-spot-at-the-lead-of-the-path-for-psychedelics-says-mindmeds-r">Find out more</a> and <a href="https://open.spotify.com/episode/1o8hafHkS3dJtqLQKPbj79">listen here</a>.
<h3 class="wp-block-heading">The Milestone Round</h3>
<ul>
<li>PharmAla&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MDXXF#OTC">MDXXF</a>) novel <a href="https://www.benzinga.com/general/biotech/24/03/37973466/pharmalas-novel-mdma-mixture-awarded-us-patent-enabling-ip-protection-and-further-development">MDMA mixture awarded US patent</a>, enabling IP protection and further development.</li>
<li>Two top biotechs forge <a href="https://www.benzinga.com/general/biotech/24/03/37945015/two-top-biotechs-forge-mdma-supply-deals-for-clinical-research">MDMA supply deals</a> for an expanding research field.</li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) optimistic on Q4 and full-year results: <a href="https://www.benzinga.com/general/biotech/24/03/37957200/enveric-biosciences-optimistic-on-q4-and-full-year-results-psychedelic-inspired-meds-for-future-g">&#8216;Psychedelic-inspired&#8217; meds</a> for future growth.</li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37898972/congress-discusses-remaining-fy2024-spending-bill-with-provisions-on-cannabis-sales-and-psychede">Congress discusses</a> remaining FY2024 spending bill with provisions on cannabis sales and psychedelic clinical trials.</li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37899722/va-calls-for-amending-medical-marijuana-bill-rejects-psychedelics-proposal">VA calls</a> for amending medical marijuana bill, rejects psychedelics proposal.</li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37811138/psychedelics-update-task-forces-in-three-states-decrim-no-go-arizona-psilocybin-centers-utah-and">Reform update</a>: Task forces in three states, decrim no-go, Arizona psilocybin centers, Utah and more.</li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37830087/goodbye-to-weed-posts-in-colorado-lawmakers-target-social-media-promotion-of-cannabis-and-psyche">Goodbye to weed posts</a> in Colorado? Lawmakers target social media promotion of cannabis and psychedelics.</li>
<li>Psychedelic-assisted therapy advancements create a new horizon for <a href="https://www.benzinga.com/markets/psychedelics/24/03/37893472/psychedelic-assisted-therapy-advancements-create-a-new-horizon-for-mental-health-in-colorado">mental health in Colorado</a>.</li>
<li>At 77, cannabis champion <a href="https://www.benzinga.com/markets/cannabis/24/03/37945441/at-77-cannabis-champion-dana-beal-fights-idaho-laws-to-push-legalization-in-hostile-territory">Dana Beal fights Idaho laws</a> to push legalization in hostile territory.</li>
<li>This biotech is creating <a href="https://www.benzinga.com/partner/biotech/24/03/37993580/this-biotech-is-creating-targeted-radiotherapuetics-for-some-of-the-deadliest-cancers">targeted radiotherapeutics</a> for some of the deadliest cancers.</li>
</ul>
See Also: <a href="https://www.benzinga.com/general/biotech/24/03/37855799/psyched-lsd-psilocybin-as-breakthrough-therapies-14m-fed-grant-for-ibogaine-indianas-research-and">Prior Edition Of ‘Psyched&#8217;</a>
<h3 class="wp-block-heading">Psychedelics ETF's Weekly Performance</h3>
AdvisorShares Psychedelics ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSIL#NYSE">PSIL</a>) opened Monday, March 25 at $1.45, following openings at $1.50, $1.65 and $1.58 (March 18, 11 and 4, respectively.)
On Thursday, March 28, it closed at $1.49, following prior closings at $1.44, $1.53 and $1.64 (March 22, 15 and 8, respectively.)
The week's highest within open market hours was $1.49, vs. prior highest points $1.55, $1.65 and $1.78.
Week's lowest (open market hours) was $1.42, vs. prior lowest points $1.41, $1.46 and $1.44. 
<h3 class="wp-block-heading">Highest Trading Psychedelics Stocks Thursday, March 28 Close</h3>
<ul>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) closed at $10.66, similar to the immediately prior week closings $10.54 and $10.91 (March 22 and 15) and jumping from and $8.08 on March 8.</li>
<li>Mind Medicine (MindMed) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) closed at $9.53, up and running as per prior closings at $9.85, $9.10 and $9.50.</li>
<li>COMPASS Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) closed at $8.33, sustaining the descending trend as per prior closings at $8.99, $9.90 and $10.88.</li>
<li>Incannex Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) closed at $3.60, a recovery from prior closings at $2.82 and $3.25, yet still not at $4.20 as three weeks ago.&nbsp;&nbsp;</li>
<li>Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) closed at $1.93, vs. prior closings at $1.63, $1.75 and $2.11.</li>
<li>Silo Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) closed at $1.92, sustaining the trend as per prior closings at $1.86, $1.84 and $1.61.</li>
<li>Lucy Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) closed at $1.39, a similar trend as per prior closings at $1.38, $1.25 and $1.70.</li>
<li>Bright Minds Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) closed at $1.20, still falling as per prior closings at $1.22, $1.31 and $1.58.</li>
<li>Clearmind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) closed at $1.15, also still falling vs. prior closings at $1.18, $1.27 and $1.38.</li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) closed at $1.03, vs. prior closings at $ 1.13, $1.07 and $1.46.</li>
</ul>
Stock trading numbers above according to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, our all-the-information-you-need streaming platform helping you invest smarter – Come join us and see for yourself!

Financing

Legal

Management

MDXXF

TSLA

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence

Clinical-stage psychedelics biotech Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) announced its consolidated financial results for the fourth quarter and full year 2023.
The Numbers:
<ul>
<li>Cash, cash equivalents and short-term investments of $154.2 million by December 31, 2023, as compared to $273.1 million by December 31, 2022.&nbsp;</li>
<li>Quarterly and full-year R&amp;D expenses of $14.2 million and $62.2 million, respectively, as compared to $21.9 million and $74.3 million for the same periods in 2022.&nbsp;</li>
<li>Quarterly and full-year General and Administrative (G&amp;A) expenses of $19.4 million and $63.6 million, respectively, as compared to $15.7 million and $70.4 million in the same periods in 2022.&nbsp;</li>
<li>Quarterly and full-year net loss of $18.3 million and $40.2 million, respectively, as compared to $45.0 million and $152.4 million in the comparable 2022 periods.</li>
</ul>
The report states that the decrease of $118.9 million in the company's cash position is primarily due to the $84.1 million net cash used in operating activities, $25.0 million for the Beckley Psytech investment, and $15.0 million of additional investments to advance its development programs.&nbsp;
Nonetheless, the Atai team <a href="https://www.benzinga.com/markets/cannabis/23/03/31494824/atai-life-sciences-hopes-hercules-can-help-sustain-operations-until-2026">still</a> expects its cash, marketable securities and <a href="https://www.benzinga.com/markets/cannabis/22/08/28502206/major-goals-for-atai-175-m-secured-in-term-loan-facility-plus-q2-earnings-report">committed term loan facility</a> with Hercules Capital for $175 million will be enough to fund operations into 2026.
Now Read: <a href="https://www.benzinga.com/markets/cannabis/23/11/35783555/atai-life-sciences-q3-earnings-near-20m-burned-qoq-says-funding-sufficient-to-streamline-2026">Atai Life Sciences&#8217; Q3 Earnings: Near $20M Burned QoQ, Says Funding &#8216;Sufficient&#8217; To Streamline 2026</a>
January's strategic investment in Beckley Psytech added two clinical-stage assets, BPL-003 and ELE-101, to Atai's programs. The company now owns 35.5% of Beckley Psytech, plus a time-limited right of first refusal on a future sale of the company, asset sales or other transfer of commercial rights and an indefinite right of first negotiation for both compounds.
Join us for the latest cannabis deals at our upcoming&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a>!&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener"></a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/28125343/2231044_CCCFloridaGIF_V2_031124-1-16.gif" alt="" class="wp-image-269503" /></a></figure>
<h3 class="wp-block-heading">‘Continued Commitment To Transforming Mental Healthcare'</h3>
The clinical-stage biopharma company is dedicated to developing innovative therapeutics to treat depression, anxiety, addiction and other mental health disorders. By pooling resources and best practices, Atai's stated aim is to responsibly accelerate the development of new medicines to achieve "clinically meaningful and sustained behavioral change" in mental health patients.
During the period, Atai reportedly underwent operational efficiencies "by simplifying and optimizing its organizational structure" in line with its revised business and pipeline priorities.
"In 2023, we demonstrated our continued commitment to transforming mental health care for those most in need. Much of our recent focus has centered on psychedelic-based therapies for depression -such as BPL-003, an intranasal formulation of 5-MeO-DMT- that require two hours or less in a clinic,&#8221; CEO and co-founder Florian Brand said. We believe that the combination of a short treatment time and durable efficacy has the potential to enable accessible and convenient interventional treatments at scale."
BPL-003 has recently shown positive initial results on a Phase 2a clinical study for Treatment-Resistant Depression (TRD,) including "rapid and durable" antidepressant effects, with 45% of patients in remission three months, following a single dose.&nbsp;
The compound will now be assessed in a multi-site Phase 2b study in 225 patients with TRD, of which topline data is expected in the second half of 2024. Plus, data from a separate Phase 2a study of BPL-003 in Alcohol Use Disorder (AUD) patients is expected mid-2024.
The other pipeline asset targeting a two-hour in-clinic treatment is VLS-01, an oral transmucosal film formulation of DMT also targeting TRD. The compound is currently being assessed in a Phase 1b study evaluating the safety and tolerability of the OTF formulation of VLS-01 as compared to intravenous DMT. Results from this study are also anticipated for H2 2024.
Other psychedelic assets in the company's portfolio with updates in the yearly period include:
<ul>
<li>ELE-101, an IV formulation of psilocin targeting Major Depressive Disorder (MDD) potentially offering psilocybin's therapeutic benefits "in a more consistent, controllable, and shorter treatment paradigm" (approx. 2 hours.) The compound is currently in a Phase 1/2a study of which results are expected by mid-2024.</li>
<li>COMP360, COMPASS Pathways' (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) synthetic psilocybin therapy, is currently under evaluation in several trials. Most noticeably within a Phase 3 program in TRD patients (topline data to come in Q4 2024 and mid-2025,) but also in a Phase 2 trial in PTSD patients (efficacy data expected by Spring 2024.)</li>
<li>IBX-210, an IV formulation of semi-synthetic ibogaine targeting Opioid Use Disorder (OUD), showed some <a href="https://www.benzinga.com/markets/cannabis/23/08/33721310/atais-q2-2023-plus-clinical-data-on-ibogaine-opioid-study-pipelines-psilocybin-dmt-ketamine-mdma">mixed results</a> in a Phase 1 study in 2023. Atai's novel IV formulation of ibogaine aims to improve safety, minimize changes in how it is processed in the body, and achieve a shorter and more predictable in-clinic time. A Phase 1/2a study of IBX-210 on OUD would begin in the second half of 2024.</li>
</ul>
Looking ahead, Brand said the company anticipates several important milestones in the coming year.
Hosted at the&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Diplomat Beach Resort</a>&nbsp;April 16- 17, the&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a>&nbsp;promises strong networking opportunities, as well as the chance to gain invaluable insights and foster growth in the cannabis industry. Renowned for its cutting-edge discussions and profound impact on the future of cannabis, this conference stands as the premier event of the year for industry professionals.&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Get your tickets now on&nbsp;</a><a href="http://bzcannabis.com/" target="_blank" rel="noreferrer noopener">bzcannabis.com</a><a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">&nbsp;– Prices will increase very soon!</a>
Photo courtesy of <a href="https://unsplash.com/@blankerwahnsinn?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Fabian Blank</a> on <a href="https://unsplash.com/photos/pink-pig-figurine-on-white-surface-pElSkGRA2NU?utm_content=creditCopyText&amp;utm_medium=referral&amp;utm_source=unsplash">Unsplash</a>.

Earnings

Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline

Partners Beckley Psytech and atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) have jointly announced positive initial results from a Phase 2a study of Beckley's novel formulation of 5-MeO-DMT in Treatment Resistant Depression (TRD.) 
See: <a href="https://www.benzinga.com/markets/cannabis/24/01/36494530/atai-invests-50m-in-beckley-psytech-for-short-duration-psychedelics-development">Atai Invests $50M In Beckley Psytech For Short-Duration Psychedelics Development</a>
BPL-003 is a synthetic and patent-protected benzoate salt formulation of 5-MeO-DMT (aka mebufotenin) designed for intranasal administration. The open-label study assessed safety, tolerability and efficacy of the compound at a single 10mg dose, alongside psychological support, in patients with moderate-to-severe TRD (who withdrew from concomitant antidepressants.) 
The study's initial findings reflect treatment of 11 participants, who were followed for 12 weeks post-dosing. Efficacy was assessed using the widely known and accepted Montgomery–Åsberg Depression Rating Scale (MADRS.)
The single 10mg dose resulted in a rapid onset and durable antidepressant effect in patients with TRD, which affects approximately 100 million people worldwide. Importantly, these findings are believed to represent the longest known follow-up of depression outcomes in a clinical study of 5-MeO-DMT.
Specifically:
<ul>
<li>BLP-003's single dose induced a rapid antidepressant response in 55% of patients on the day after dosing. The antidepressant effect lasted, with a 55% response rate maintained at Week 4 and further on to Week 12.&nbsp;</li>
<li>55% of patients were in remission at Week 4, and 45% in remission at Week 12.&nbsp;</li>
<li>BPL-003 showed a good safety profile and was well tolerated. Adverse events (AEs) were predominantly mild or moderate and the most common AEs (&gt;10%) were nasal discomfort, headaches, nausea and vomiting, broadly consistent with Phase 1 findings. No serious AEs were reported.</li>
<li>Acute effects resolved on average in less than two hours.&nbsp;</li>
<li>Altogether, data suggest BPL-003 could offer a shorter in-clinic treatment time vs. other psychedelic treatments in development.</li>
</ul>
<h3 class="wp-block-heading">Management Comments &amp; Next In Progress</h3>
Get the latest on cannabis research at our upcoming <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a>! <a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener"></a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/03/27153107/2231044_CCCFloridaGIF_V2_031124-1-12.gif" alt="" class="wp-image-267976" /></a></figure>
Beckley Psytech's CEO Cosmo Feilding Mellen said the team is thrilled with the evidence that a single dose of BPL-003 delivered a rapid and durable antidepressant response in patients with TRD. 
"Our single dose treatment model enables a short treatment duration which positions BPL-003 as a potentially exciting and scalable treatment opportunity," said Feilding Mellen, adding that less than 15% of patients with TRD achieve long-term remission with the current standard of care. 
A randomized, quadruple-masked, controlled Phase 2b study of BPL-003 is currently underway. Its aim is to investigate the effects of a single 12mg or 8mg dose, vs. a sub-perceptual dose of 0.3mg, in 225 patients with TRD. 
Efficacy will be assessed by masked raters using the MADRS scale at several time points, the primary endpoint at Week 4 and final assessment at Week 8. Topline results are expected in the second half of 2024.
"We look forward to further validating the potential of BPL-003 as a treatment option with our ongoing Phase IIb study and subsequent clinical development program," Feilding Mellen concluded.
On atai's end, CEO and co-founder Florian Brand highlighted the company's particular excitement over BLP-003's antidepressant durability potential. 
"The results indicate that BPL-003 could offer a scalable, single-dose administration within the two hour in-clinic treatment paradigm successfully established by Spravato," Brand said, to later be <a href="https://twitter.com/C_Angermayer/status/1773013930937376959">echoed</a> by founder and chairman Christian Angermayer. 
Separately, a Part 2 extension of Beckley's Phase 2a open-label study is now enrolling patients with TRD who are on stable doses of oral antidepressants to assess the safety and efficacy of BPL-003 co-administration.
Photo: Benzinga edit with photos by Nynke van Holten on Shutterstock and Harbin on Wikimedia Commons.
Hosted at the&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Diplomat Beach Resort</a>&nbsp;April 16- 17, the&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Benzinga Cannabis Capital Conference</a>&nbsp;promises strong networking opportunities, as well as the chance to gain invaluable insights and foster growth in the cannabis industry. Renowned for its cutting-edge discussions and profound impact on the future of cannabis, this conference stands as the premier event of the year for industry professionals.&nbsp;<a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">Get your tickets now on&nbsp;</a><a href="http://bzcannabis.com/" target="_blank" rel="noreferrer noopener">bzcannabis.com</a><a href="https://www.benzinga.com/events/cannabis-conference/" target="_blank" rel="noreferrer noopener">&nbsp;– Prices will increase very soon!</a>

Intranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant Depression

ATAI Life Sciences shares are trading higher after the company reported better-than-expected Q4 EPS results.

ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) reported its Q4 earnings results on Thursday, March 28, 2024 at 07:00 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
ATAI Life Sciences beat estimated earnings by 25.0%, reporting an EPS of $-0.12 versus an estimate of $-0.16.
Revenue was down $20 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.06 which was followed by a 4.0% drop in the share price the next day.

To track all earnings releases for ATAI Life Sciences <a href="https://www.benzinga.com/quote/ATAI/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: ATAI Life Sciences Q4 Earnings

ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.16) by 25 percent. This is a 57.14 percent increase over losses of $(0.28) per share from the same period last year. The company reported quarterly sales of $18.00 thousand which missed the analyst consensus estimate of $190.00 thousand by 90.53 percent. This is a 52.63 percent decrease over sales of $38.00 thousand the same period last year.

ATAI Life Sciences Q4 EPS $(0.12) Beats $(0.16) Estimate, Sales $18.00K Miss $190.00K Estimate

HC Wainwright &amp; Co. analyst Patrick Trucchio maintains ATAI Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) with a Buy and maintains $20 price target.

HC Wainwright & Co. Maintains Buy on ATAI Life Sciences, Maintains $20 Price Target

<h3 class="wp-block-heading">FDA Grants Cybin Breakthrough Therapy Status For Major Depression Psilocybin Therapy, Company Announces Positive Clinical Data &amp; Canadian $150M Private Placement</h3>
Clinical-stage psychedelics biopharma company Cybin Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYBN#NYSE">CYBN</a>) announced that the Food and Drug Administration has granted Breakthrough Therapy designation to CYB003, its proprietary deuterated psilocybin analog targeting the adjunctive treatment of Major Depressive Disorder (MDD.)&nbsp;
It makes the group of psychedelic-based treatments for mental health conditions that have in recent years received such status granted by the U.S. federal agency five therapies total: Cybin's, MindMed's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) LSD-derived treatment for Generalized Anxiety Disorder, MAPS&#8217; MDMA-assisted therapy for PTSD treatment, Compass Pathways&#8217; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) psilocybin therapy targeting Treatment-Resistant Depression (TRD,) and Usona Institute's psilocybin therapy for MDD as well. <a href="https://www.benzinga.com/general/biotech/24/03/37665900/fda-grants-cybin-breakthrough-therapy-status-for-major-depression-psilocybin-therapy-company-anno">READ MORE</a>.
<h3 class="wp-block-heading">MindMed Receives FDA &#8216;Breakthrough Therapy&#8217; Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials And Expected $175M Proceeds</h3>
Mind Medicine (MindMed) announced that the FDA has granted the &#8220;<a href="https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy">breakthrough therapy</a>&#8221; designation to its MM120 (lysergide d-tartrate) program for the treatment of Generalized Anxiety Disorder (GAD).&nbsp;
The company stated that, based on the significant unmet medical need in the treatment of GAD, especially in patients who do not respond to or tolerate currently available medications, this news as well as initial clinical data from other research, the FDA has designated MM120 for GAD as a breakthrough therapy. <a href="https://www.benzinga.com/general/biotech/24/03/37542756/mindmed-receives-fda-breakthrough-therapy-designation-for-lsd-as-anxiety-treatment-shares-positiv">READ MORE</a>.
Shortly following the news, the company announced the pricing of an underwritten offering of 16,666,667 common shares, no par value per share, at an offering price of $6.00 each. It has also entered into share purchase agreements for a concurrent private placement of 12,500,000 common shares.
Total gross proceeds, from the underwritten offering and the concurrent private placement are expected to be around $175 million. <a href="https://www.benzinga.com/general/biotech/24/03/37565302/mindmeds-systematic-biotech-approach-with-new-fda-therapy-designation-12-week-clinical-data-plus-">READ MORE</a>.
<h3 class="wp-block-heading">Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use Disorder</h3>
Clinical-stage neuroscience company Gilgamesh Pharmaceuticals has been awarded a multi-year $14 million grant from the National Institute on Drug Abuse (NIDA) to develop GM-3009, a novel, reportedly cardiac-safe ibogaine analog for the treatment of substance use disorders.&nbsp;
As recently reported in the York Times, the plant-derived psychoactive compound ibogaine holds accumulated data from trials and case reports that point to its robust efficacy as a treatment for substance use disorders. <a href="https://www.benzinga.com/general/biotech/24/03/37757899/fed-agency-grants-14m-to-gilgamesh-for-cardiac-safe-ibogaine-analog-targeting-opioid-use-disorder">READ MORE</a>.
<h3 class="wp-block-heading">Indiana Governor Signs Health Bill Including State Funds For Psilocybin Research</h3>
Indiana Gov. Eric J. Holcomb (R) acted swiftly on the passing of a health bill, which includes provisions to fund clinical research trials into psilocybin. Sent by the state legislators to his desk on March 12, the governor <a href="https://iga.in.gov/legislative/2024/bills/house/1259/actions">officially</a> signed the proposal into law the following day, March 13.
The bill, HB 1259, with final amendments adding the psychedelics language – originally SB 139 passed the Senate and the House&#8217;s Public Health committee – received the green light from both state chambers on March 12. <a href="https://www.benzinga.com/markets/cannabis/24/03/37758041/indiana-governor-signs-health-bill-including-state-funds-for-psilocybin-research">READ MORE</a>.
<h3 class="wp-block-heading">The Milestone Round</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) will undertake <a href="https://www.benzinga.com/general/biotech/24/03/37603637/psyence-biomedical-will-undertake-psilocybin-clinical-trials-for-palliative-care-in-australia">psilocybin clinical trials for palliative care</a> in Australia.</li>
<li>Denver to become <a href="https://www.benzinga.com/markets/cannabis/24/03/37604069/maps-and-city-of-denver-will-train-first-responders-in-psychedelics-crisis-intervention">first US city to train first responders</a> in psychedelics crisis intervention.</li>
<li>Truffles to market: Red Light Holland (OTC:<a class="ticker" href="https://www.benzinga.com/stock/TRUFF#OTC">TRUFF</a>) wants to develop <a href="https://www.benzinga.com/markets/cannabis/24/03/37588896/truffles-to-market-red-light-holland-wants-to-develop-psilocybin-api-at-scale">psilocybin API at scale</a>.</li>
<li>Podcast: Clearmind&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) non-hallucinogenic psychoactive molecule could become <a href="https://www.benzinga.com/general/biotech/24/03/37628765/podcast-clearminds-non-hallucinogenic-psychoactive-molecule-could-become-a-solution-for-addictive">a solution for addictive behaviors</a>.</li>
<li>From isolation to integration: the case for <a href="https://www.benzinga.com/markets/cannabis/24/03/37596961/from-isolation-to-integration-the-case-for-group-ketamine-therapy-with-zappy-zapolin">group ketamine therapy</a> with Zappy Zapolin.</li>
<li>CEO of a <a href="https://www.benzinga.com/partner/cryptocurrency/24/03/37741056/ceo-of-leading-canadian-cryptocurrency-business-excited-about-the-future-of-the-market">leading Canadian cryptocurrency business</a> is excited about the future of the market.</li>
<li><a href="https://www.benzinga.com/markets/cannabis/24/03/37636343/michigan-cops-bust-one-of-the-largest-illegal-weed-grow-operations-to-date">Michigan cops</a> bust one of the largest illegal weed grow operations to date.</li>
<li>What&#8217;s going on with <a href="https://www.benzinga.com/news/24/03/37564279/whats-going-on-with-psyence-biomedical-stock">Psyence Biomedical</a> stock? (March 8, 2024)</li>
<li><a href="https://www.benzinga.com/general/biotech/24/03/37515121/psychedelics-2024-veterans-blessing-mental-health-paradigm-shift-providers-training-ketamine-mdma">Psychedelics 2024</a>: Veterans blessing, mental health paradigm shift, providers training, ketamine-MDMA bonds &amp; more.</li>
<li>Why do magic mushrooms <a href="https://www.benzinga.com/markets/cannabis/24/03/36204395/why-do-magic-mushrooms-bruise-blue-science-solves-the-mystery">bruise blue</a>? Science solves the mystery.</li>
</ul>
See Also: <a href="https://www.benzinga.com/markets/cannabis/24/03/37465047/psyched-new-evidence-shows-psilocybin-as-anxiety-therapy-open-source-learning-for-therapists-env">Prior Edition Of ‘Psyched'</a>
<h3 class="wp-block-heading">Psychedelics ETF&#8217;s Weekly Performance</h3>
AdvisorShares Psychedelics ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PSIL#NYSE">PSIL</a>) opened Monday, March 18 at $1.50, following prior openings at $1.65, $1.58, and $1.46 (March 11, 4 and Feb. 26, respectively.)
On Friday, March 15 it closed at $1.53, following prior closings at $1.64, $1.57 and $1.41 (March 8, 1 and Feb. 23, respectively.)
Last week&#8217;s highest was $1.65, at Tuesday, March 12 closing. Prior weeks' highests were $1.78, $1.57 and $1.52.
Week&#8217;s lowest was $1.46 at several points during the week. Prior weeks' lowests were $1.44, $1.43 and $1.41.
<h3 class="wp-block-heading">Highest Trading Psychedelics Stocks Friday, March 15 Close</h3>
<ul>
<li>GH Research (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GHRS#NASDAQ">GHRS</a>) closed at $10.91, sustaining the upper trend as per prior weekly closings at $8.08, $8.50 and $7.51 (March 8, 1 and Feb. 23, respectively.)</li>
<li>COMPASS Pathways closed at $9.90, down from prior closings at $10.88, $11.47 and $10.20.</li>
<li>Mind Medicine (MindMed) closed at $9.10, still jumping as per prior closings at $9.10, slightly behind the immediate prior week's closing at $9.50 yet still way high as from two and three weeks past closings at $6.21 and $4.91.</li>
<li>Incannex Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IXHL#NASDAQ">IXHL</a>) closed at $3.25, dropping from prior closings at $4.20, $5.37 and $4.84.&nbsp;</li>
<li>Silo Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILO#NASDAQ">SILO</a>) closed at $1.84, still up from prior closings at $1.61, $1.59 and $1.57.&nbsp;</li>
<li>Atai Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) closed at $1.75, also dropping from prior weekly closings at $2.11, $2.14 and $1.83.</li>
<li>Bright Minds Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRUG#NASDAQ">DRUG</a>) closed at $1.31, still within the decreasing trend as per prior closings at $1.58, $1.76 and $1.88.</li>
<li>Clearmind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) closed at $1.27, also still falling from prior closings at $1.38, $1.60 and $1.81.</li>
<li>Lucy Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSDI#NASDAQ">LSDI</a>) closed at $1.25, following closings at $1.70, $1.91 and $2.42.</li>
<li>Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) closed at $1.07, following closings at $1.46, $1.62 and $0.95.</li>
</ul>
Stock trading numbers above according to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, our all-the-information-you-need streaming platform helping you invest smarter – Come join us and see for yourself!
Now Read <a href="https://www.benzinga.com/general/biotech/24/03/37765991/psychedelics-headlines-substitution-survey-frank-herberts-magic-mushrooms-celestial-plans-and-new">Psychedelics Headlines:&nbsp;Substitution Survey, Frank Herbert&#8217;s Magic Mushrooms, Celestial Plans And News Review</a>

CYBN

RED LIGHT HOLLAND CORP by Red Light Holland Corp.

TRUFF

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More

Welcome to Benzinga's psychedelic headlines roundup. This is our pick of must-read news items concerning the first two weeks of March 2024.
See previous edition <a href="https://www.benzinga.com/markets/cannabis/24/03/37435613/psychedelics-headlines-predicting-readiness-correcting-the-hype-good-and-bad-drugs-training-prog">Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More</a>.
<h3 class="wp-block-heading">Research</h3>
<ul>
<li>The therapeutic alliance between study participants and intervention facilitators is associated with acute effects and clinical outcomes in a psilocybin-assisted therapy trial for major depressive disorder (<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300501">original read</a>.)</li>
<li>Review: Making sense of psychedelics in the CNS (<a href="https://academic.oup.com/ijnp/article/27/2/pyae007/7592054?utm_source=etoc&amp;utm_campaign=ijnp&amp;utm_medium=email&amp;login=false">original read</a>.)</li>
<li>The effect of psilocybin on empathy and prosocial behavior: a proposed mechanism for enduring antidepressant effects (<a href="https://www.nature.com/articles/s44184-023-00053-8">original read</a>.)</li>
<li>Perceived attachment history predicts psychedelic experiences: A naturalistic study (<a href="https://akjournals.com/view/journals/2054/aop/article-10.1556-2054.2024.00330/article-10.1556-2054.2024.00330.xml">original read</a>.)</li>
<li>Psychiatric risks for worsened mental health after psychedelic use (<a href="https://journals.sagepub.com/doi/10.1177/02698811241232548">original read</a>.)</li>
<li>Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey (<a href="https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsyt.2024.1349565/full">original read</a>.)</li>
<li>Diminished psychedelic returns on distress: Marital status and household size (<a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0293675">original read</a>.)</li>
</ul>
<h3 class="wp-block-heading">Tune In, Get Smart</h3>
<ul>
<li>Mushroom Extract Outperforms Synthetic Psilocybin in Psychiatric Therapy, by Neuroscience News (<a href="https://neurosciencenews.com/psilocybin-mental-health-25739/">read</a>.)</li>
<li>UN Body Reaffirms that Marijuana Legalization Violates International Treaties while Addressing Germany Cannabis Reform and U.S. Psychedelics Movement, by Marijuana Moment (<a href="https://www.marijuanamoment.net/un-body-reaffirms-that-marijuana-legalization-violates-international-treaties-while-addressing-germany-cannabis-reform-and-u-s-psychedelics-movement/">read</a>.)</li>
<li>Bioethics, Psychedelic Therapy Abuse, and the Risk of Ethics Washing, by Harvard's Petrie Flom Center (<a href="https://blog.petrieflom.law.harvard.edu/2024/03/01/bioethics-psychedelic-therapy-abuse-and-the-risk-of-ethics-washing/">read</a>.)</li>
<li>Psychedelic Lobbying and Regulatory Capture, by Vincent Joralemon for Petrie Flom (<a href="https://blog.petrieflom.law.harvard.edu/2024/03/04/psychedelic-lobbying-and-regulatory-capture/">read</a>.)</li>
<li>Frank Herbert's Magic Mushrooms and the Psychedelic Science Behind Dune, by The Telegraph (<a href="https://www.telegraph.co.uk/films/0/dune-frank-herbert-magic-mushrooms-spice-science/">read</a>.)</li>
<li>AA Founder Bill Wilson Did Not Use Psychedelics to Get Sober, by the Chemical Collective (<a href="https://chemical-collective.com/blog/aa-founder-bill-wilson-did-not-use-psychedelics-to-get-sober/">read</a>.)</li>
<li>Psychedelic Legacies of American Religion: A review of Psychedelic Cults and Outlaw Churches by Mike Marinacci, by Psychedelic Press (<a href="https://psychedelicpress.substack.com/p/psychedelic-cults">read</a>.)</li>
<li>New Mexico Is a Psychedelic Hologram of Ancient Origins and People, by DoubleBlind Mag (<a href="https://doubleblindmag.com/new-mexico-hologram/">read</a>.)</li>
<li>Psychedelic Therapy: Empowering Ukraine's Mental Health Frontlines, by The Dales Report (<a href="https://thedalesreport.com/psychedelics/psychedelic-therapy-empowering-ukraines-mental-health-frontlines/">read</a>.)</li>
<li>Ketamine Clinics Diverge from APA Recommendations, by Medpage Today (<a href="https://www.medpagetoday.com/special-reports/exclusives/109012?xid=nl_mpt_DHE_2024-03-04&amp;eun=g334211d0r&amp;utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Daily%20Headlines%20Evening%202024-03-04&amp;utm_term=NL_Daily_DHE_dual-gmail-definition">read</a>.)</li>
<li>China's Emerging Psychedelic Scene Looks a Lot Like Silicon Valley, by Vox (<a href="https://www.vox.com/future-perfect/24091676/psychedelics-china-capitalism-silicon-valley-ayahuasca">read</a>.)</li>
<li>Navigating Legal Clarity on Ayahuasca in Portugal, by The International Center for Ethnobotanical Education, Research and Service (ICEERS) (<a href="https://www.iceers.org/navigating-legal-clarity-ayahuasca-portugal/">read</a>.)</li>
<li>Cocaine Use Doubles in NZ: &#8216;A Big Change in a Short Space of Time&#8217;, by RNZ (<a href="https://www.rnz.co.nz/news/national/510952/cocaine-use-doubles-in-nz-a-big-change-in-a-short-space-of-time">read</a>.)</li>
<li>‘In a Way, Stigma is the Leading Cause of Death': The Radical Plan to Tackle British Columbia's Overdose Epidemic by The Guardian (<a href="https://www.theguardian.com/world/2024/mar/07/legal-challenge-pure-drugs-overdose-british-columbia-canada?CMP=share_btn_url">read</a>.)</li>
<li>"The Tao of the Wisdom Warrior" &#8211; The McKenna Academy's podcast with Tom Pinkson (<a href="https://mckenna.academy/mka-podcast/the-tao-of-the-wisdom-warrior/">listen</a>.)</li>
<li>New podcast by Plantscendence hosted by filmmaker Jon Reiss is out, with James Fadiman featuring within the first episodes (<a href="https://plantscendence.com/">listen</a>.)&nbsp;</li>
<li>Opioid scientist at Johns Hopkins Medicine and Maryland Opioid Research Kelly Dunn will speak at nonprofit <a href="https://twitter.com/innovations4sud">Innovations for Substance Use Disorders</a> next webinar on March 21 (<a href="https://www.i4sud.com/events/xylazine">register</a>.)</li>
<li>UC Berkeley Center for the Science of Psychedelics (UC-BCSP) is hosting an online event on contemporary psychedelic research on March 27 (<a href="https://psychedelics.berkeley.edu/research-spotlight-the-future-of-psychedelic-science-at-uc-berkeley/">register</a>.)</li>
<li>Music for Psychedelic Integration with Jon Hopkins, Dr. Rosalind Watts and the Acer Community is taking place online April 4 (<a href="https://dandelion.events/e/acermusic/">register</a>.)</li>
<li>MAPS is celebrating its 38th anniversary on April 8 with a total solar eclipse at the Texas Eclipse 2024 (<a href="https://maps.org/2024/03/07/maps38xte24/">details</a>.)</li>
<li>The Boston Psychoanalytic Society and Institute is launching a course on The Role of Psychoanalysis in Psychedelic Assisted Psychotherapy, starting April 9 (<a href="https://myemail.constantcontact.com/The-Role-of-Psychoanalysis-in-Psychedelic-Assisted-Psychotherapy---Explorations-in-Mind-2023-2024-.html?soid=1102168755826&amp;aid=IsoMvJsFyCo">details</a>.)&nbsp;</li>
<li>UK nonprofit Drug Science's Women in Psychedelics online webinar is taking place April 11 (<a href="https://www.eventbrite.co.uk/e/women-in-psychedelics-tickets-853001990917?aff=oddtdtcreator">register</a>.)</li>
<li>Livestream tickets for Breaking Convention's 2024 edition taking place April 20 are available (<a href="https://www.tickettailor.com/events/breakingconvention/1167843">details</a>.)</li>
<li>Chacruna Institute's Annual Spring Conference on Plant Medicines &amp; Psychedelic Science will take place in San Francisco's Brava Theater on April 27-28 (<a href="https://chacruna.net/psychedelic-culture-pcu24/">details</a>.)</li>
<li>Applications are open for Harvard Law School Center's three-day Psychedelics Bootcamp 2024 on legal, ethical and policy issues surrounding psychedelics in medicine and society until March 31 (<a href="https://petrieflom.law.harvard.edu/resources/opportunity/psychedelics-bootcamp-2024">details</a>.)</li>
<li>Applications are open for the 2024-2025 Certificate in Psychedelic-Assisted Therapies and Research at California Institute of Integral Studies (CIIS) until April 22, scholarships available (<a href="https://www.ciis.edu/research-centers-and-initiatives/center-for-psychedelic-therapies-and-research/about-the-certificate?fbclid=IwAR0k_axqNCVJcbH_aCOegBve2l444cgjtBy8bg_Ml-2XCi0JZVAeFxdrvc8">details</a>.)</li>
<li>UK's Leeds Beckett University is conducting a survey on experienced deep personal transformation/profound change in worldview as a result of engaging with self-development via meditation, psychedelics or other transpersonal practices (<a href="https://twitter.com/HumaNatureWorld/status/1765011048703164757">contact</a>.)&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Panorama Pulse</h3>
<ul>
<li>Clearmind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMND#NASDAQ">CMND</a>) obtained <a href="https://www.clearmindmedicine.com/news-release/clearmind-medicine-obtains-clearance-for-its-psychedelic--based-alcoholism-clinical-trial">clearance for its psychedelic-based alcoholism clinical trial</a> in Israel, and received approval for a <a href="https://www.clearmindmedicine.com/news-release/clearmind-medicine-received-approval-for-a-voluntary-delisting-of-its-common-shares-from-the-canadian-securities-exchange#:~:text=Vancouver%2C%20Canada%2C%20March%2013%2C%202024%20--%20Clearmind%20Medicine,common%20shares%20from%20the%20Canadian%20Securities%20Exchange%20%28%22CSE%22%29.">voluntary delisting of its common shares from the CSE</a>.</li>
<li><a href="https://ir.atai.life/news-releases/news-release-details/atai-life-sciences-announces-first-participant-dosed-phase-1b">atai Life Sciences</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATAI#NASDAQ">ATAI</a>) announced the first participant was dosed in its Phase 1b trial of VLS-01.</li>
<li><a href="https://www.nasdaq.com/press-release/betterlifes-2-bromo-lsd-for-treatment-of-depression-highlighted-by-carleton">BetterLife's</a> (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/BETRF#OTCQB">BETRF</a>) 2-Bromo-LSD for treatment of depression was highlighted by Carleton University in a recent article.</li>
<li><a href="https://www.investors.numinus.com/news/news-details/2024/Numinus-Wellness-Provides-Corporate-Update/default.aspx">Numinus Wellness</a> (OTC:<a class="ticker" href="https://www.benzinga.com/stock/NUMIF#OTC">NUMIF</a>) provided a corporate update.</li>
<li><a href="https://www.enveric.com/news/enveric-biosciences-announces-new-patent-issuances-protecting-multiple-assets-covered-by-non-binding-term-sheets/">Enveric Biosciences</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) announced new patent issuances protecting multiple assets covered by non-binding term sheets.</li>
<li><a href="https://finance.yahoo.com/news/fsd-pharma-submits-phase-1b-120000397.html">FSD Pharma</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUGE#NASDAQ">HUGE</a>) submitted a Phase 1b clinical trial application to the Ethics Committee for its proprietary beverage unbuzzd, and presented <a href="https://finance.yahoo.com/news/fsd-pharma-presents-positive-results-130000324.html">positive results</a> on its first clinical study of Lucid-21-302 (Lucid-MS) at the ACTRIMS forum.</li>
<li>Canadian biotech <a href="https://finance.yahoo.com/news/apex-labs-files-us-patent-150700971.html">Apex Labs</a> filed for a U.S. patent protecting its psychedelic drug delivery system.</li>
<li><a href="https://finance.yahoo.com/news/beckley-waves-celebrates-milestones-including-140000480.html">Beckley Waves</a> celebrates a year of milestones including $3.3 million in new funding, 200 retreat participants, the inaugural cohort of therapist training and the acquisition of ketamine therapy provider Nue Life.</li>
<li>Psilocybin producer <a href="https://finance.yahoo.com/news/rose-hill-leads-way-psilocybin-140000414.html">Rose Hill</a> is paving the way with innovative geo-thermal cultivation enhancements in Jamaica.</li>
<li>Optimi Health&#8217;s (OTC:<a class="ticker" href="https://www.benzinga.com/stock/OPTHF#OTC">OPTHF</a>) psilocybin cultivation and analytical lab was <a href="https://www.youtube.com/watch?v=TjYObKHqDQI&amp;ab_channel=GrowingExposed">showcased</a> at Growing Exposed (Season 4, Ep. 4).</li>
</ul>

Global

BETRF

MASSIVE INTERACTIVE NV by Massive Interactive, Inc.

HUGE

NUMIF

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review

<a href="https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/">https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/</a>
&nbsp;
The Indiana legislature has sent a bill to the governor&#39;s desk that includes provisions to fund clinical research trials into psilocybin.
The House and Senate both passed the underlying legislation on health care issues, which was amended to add the psychedelics language, last week.
The reform provisions that lawmakers attached to the broader legislation were taken from a standalone measure from Sen. Ed Charbonneau (R) that <a href="https://www.marijuanamoment.net/indiana-senate-passes-gop-led-psilocybin-research-bill-with-democrats-filing-but-not-forcing-vote-on-medical-marijuana-amendment/">cleared the Senate last month</a> <a href="https://www.marijuanamoment.net/indiana-house-panel-approves-psilocybin-research-bill-that-already-passed-full-senate/">and then advanced through a House committee</a>.
Charbonneau <a href="https://www.indianasenaterepublicans.com/statement-from-state-sen-ed-charbonneau-1">said</a> in a press release on Friday that the intent of the proposal is to provide funding to &quot;aid Indiana research institutions in studying the potential use of psilocybin in treating mental health and other medical conditions, especially in veterans and first responders.&quot;
Under the amended bill that&#39;s now going to Gov. Eric Holcomb (R), the state would create a therapeutic psilocybin research fund &quot;for the purpose of providing financial assistance to research institutions in Indiana to study&hellip;the use of psilocybin to treat mental health and other medical conditions.&quot;
Any research receiving funding under the legislation would need to include veterans and first responders regarding in the study sample.
Researchers would need to apply to the state Department of Health to receive funds to study the substance as a treatment for conditions, several of which are specified in the bill as introduced: PTSD &quot;with a focus on treating the disorder in combat veterans and first responders,&quot; anxiety, depression, bipolar disorder, chronic pain and migraines.
Alcohol use disorder and tobacco use disorder were added to list of conditions in the standalone bill in committee, and that updated language was also incorporated into the amendment to the enacted health care legislation.
The studies supported by the legislation would need to &quot;compare the efficacy of psilocybin as a treatment for mental health and other medical conditions&hellip;with the efficacy of other current treatment options.&quot;
The <a href="https://iga.in.gov/legislative/2024/bills/house/1259/details">proposal</a> would become effective immediately upon passage. Officials would need to establish a process to administer the fund and process applications by July 1.
A state-created study committee recently&nbsp;<a href="https://www.marijuanamoment.net/indiana-legislative-committee-recommends-launch-of-psilocybin-assisted-therapy-pilot-program/">recommended that lawmakers authorize a psilocybin pilot program</a>&nbsp;to research psychedelic-assisted therapy for mental health during this year&#39;s legislative session, advising that &quot;the Indiana General Assembly take an approach that strikes a balance between access, research, and prudence.&quot;
While psilocybin is classified as a Schedule I controlled substance at the federal level, the body said, the &quot;prevailing view is that psilocybin should not be a Schedule I drug and has proven medical benefits.&quot;
Charbonneau, the sponsor of the standalone psilocybin measure, said late last year that he was already in touch with people at Indiana University Health and Purdue University about psychedelic research.
Indiana lawmakers have been considering marijuana legalization but so far have yet to take concrete steps toward the reform in the GOP-controlled legislature. Another interim study group&nbsp;<a href="https://www.marijuanamoment.net/indiana-lawmakers-mull-marijuana-legalization-at-six-hour-committee-meeting-but-fail-to-make-recommendations/">heard testimony around the possibility of decriminalizing simple cannabis possession</a>&nbsp;in November, but the group did not make any specific recommendations.
In an op-ed for Marijuana Moment, Rep. Blake Johnson (D) wrote recently that&nbsp;<a href="https://www.marijuanamoment.net/indiana-is-falling-far-behind-on-marijuana-as-neighboring-states-legalize-lawmaker-says-op-ed/">Indiana is &quot;falling far behind&quot; on marijuana</a>&nbsp;as its neighboring states legalize. &quot;I implore my fellow legislators to listen to the statistics. It&#39;s time for Indiana to sow the seeds and reap the economic benefits of cannabis,&quot; he wrote.
One supportive lawmaker&mdash;Rep. Justin Moed (D)&mdash;managed to&nbsp;<a href="https://www.marijuanamoment.net/indiana-democrat-forces-marijuana-legalization-vote-in-house-but-gop-lawmakers-reject-it/">force a vote on marijuana legalization in the House</a>&nbsp;last year, but Republicans rejected the proposal.
On psychedelics, Indiana is just one of a growing number of states where lawmakers are pursuing reform, with a focus on research and therapeutic access.
&nbsp;
For example, on Wednesday the Maryland House of Delegates <a href="https://www.marijuanamoment.net/maryland-committees-take-up-psychedelics-and-drug-decriminalization-task-force-bills/">passed a bill to create a psychedelics task force responsible for studying possible regulatory frameworks</a>&nbsp;for therapeutic access to substances such as psilocybin, mescaline and DMT. It would be charged specifically with ensuring &quot;broad, equitable and affordable access to psychedelic substances&quot; in the state.
On Monday an Arizona House panel approved a Senate-passed bill to <a href="https://www.marijuanamoment.net/arizona-senate-passes-bill-to-legalize-psilocybin-service-centers-where-people-could-use-the-psychedelic-in-a-supervised-setting/">legalize psilocybin service centers where people could receive the psychedelic</a>&nbsp;in a medically supervised setting.
Utah lawmakers last week unanimously approved a Republican-led bill to <a href="https://www.marijuanamoment.net/utah-lawmakers-unanimously-approve-bill-to-allow-psilocybin-and-mdma-treatment-at-hospitals-sending-it-to-the-governor/">authorize a pilot program for hospitals to administer psilocybin and MDMA</a> as an alternative treatment option, sending it to the governor.
Also last week a Missouri House committee unanimously <a href="https://www.marijuanamoment.net/missouri-lawmakers-approve-bill-to-legalize-psilocybin-therapy-for-veterans/">approved a bill to legalize the medical use of psilocybin by military veterans</a>&nbsp;and fund studies exploring the therapeutic potential of the psychedelic.
Connecticut lawmakers held a hearing on a bill to&nbsp;<a href="https://www.marijuanamoment.net/connecticut-lawmakers-consider-psilocybin-decriminalization-bill-in-joint-committee-hearing/">decriminalize possession of psilocybin</a>&nbsp;last week.
A&nbsp;<a href="https://www.marijuanamoment.net/vermont-lawmakers-consider-removing-psilocybin-legalization-provision-from-psychedelic-study-group-bill/">Vermont legislative panel continued its consideration this month of a bill</a>&nbsp;that would&nbsp;<a href="https://www.marijuanamoment.net/vermont-lawmakers-take-up-proposal-to-decriminalize-psilocybin-and-explore-legalizing-psychedelic-assisted-therapy/">legalize psilocybin in the state and establish a work group</a>&nbsp;on how to further regulate psychedelics for therapeutic use.
The governor of New Mexico recently endorsed a newly enacted resolution&nbsp;<a href="https://www.marijuanamoment.net/new-mexico-senate-passes-psilocybin-therapy-and-research-resolution-in-unanimous-vote/">requesting that state officials research the therapeutic potential of psilocybin</a>&nbsp;and explore the creation of a regulatory framework to provide access to the psychedelic.
An Illinois senator&nbsp;<a href="https://www.marijuanamoment.net/illinois-bill-would-legalize-psilocybin-and-create-service-centers-with-plans-to-add-more-psychedelics-to-the-program/">recently introduced a bill to legalize psilocybin and allow regulated access</a>&nbsp;at service centers in the state where adults could use the psychedelic in a supervised setting&mdash;with plans to expand the program to include mescaline, ibogaine and DMT.
Alaska House and Senate committees are considering legislation that would create a task force to&nbsp;<a href="https://www.marijuanamoment.net/alaska-house-panel-advances-proposal-to-create-a-psychedelics-task-force-in-anticipation-of-federal-legalization/">study how to license and regulate psychedelic-assisted therapy</a>&nbsp;in anticipation of eventual federal legalization of substances like MDMA and psilocybin.
Lawmakers in Hawaii are also continuing to advance a bill that would&nbsp;<a href="https://www.marijuanamoment.net/hawaii-panel-advances-therapeutic-psilocybin-bill-that-would-protect-patients-from-penalties/">provide some legal protections to patients engaging in psilocybin-assisted therapy</a>&nbsp;with a medical professional&#39;s approval.
New York lawmakers also said that a bill to legalize psilocybin-assisted therapy in that state&nbsp;<a href="https://www.marijuanamoment.net/new-york-lawmakers-say-bill-to-legalize-psilocybin-assisted-therapy-has-a-real-chance-to-advance-this-year/">has a &quot;real chance&quot; of passing this year</a>.
Bipartisan California lawmakers also recently introduced a bill to legalize psychedelic service centers where adults 21 and older could&nbsp;<a href="https://www.marijuanamoment.net/bipartisan-california-lawmakers-file-bill-to-legalize-psychedelic-services-with-hopes-of-finding-common-ground-with-governor/">access psilocybin, MDMA, mescaline and DMT in a supervised environment</a>&nbsp;with trained facilitators.
A Nevada joint legislative committee held a hearing with&nbsp;<a href="https://www.marijuanamoment.net/nevada-lawmakers-hear-testimony-on-therapeutic-benefits-of-psychedelics-and-law-enforcement-concerns-about-legalization/">expert and public testimony on the therapeutic potential of substances like psilocybin</a>&nbsp;in January. Law enforcement representatives also shared their concerns around legalization&mdash;but there was notable acknowledgement that some reforms should be enacted, including possible rescheduling.
The governor of Massachusetts recently&nbsp;<a href="https://www.marijuanamoment.net/massachusetts-governor-touts-activists-support-for-her-veterans-bill-that-would-create-psychedelics-work-group/">promoted the testimony of activists who spoke in favor of her veterans-focused bill</a>&nbsp;that would, in part, create a psychedelics work group to&nbsp;<a href="https://www.marijuanamoment.net/massachusetts-governor-files-bill-to-create-psychedelic-therapy-working-group-for-veterans-as-activists-push-legalization-on-ballot/">study the therapeutic potential of substances such as psilocybin</a>.
&nbsp;

SEEL

Reported Earlier, 'Indiana Lawmakers Send Psilocybin Research Funding Bill To Governor' - Marijuana Moment

ATAI Life Sciences (ATAI – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Patrick Trucchio ...

Buy Rating Affirmed for ATAI Life Sciences on Promising TRD Treatment Trial Outcomes and Strong Valuation Prospects

ATAI Life Sciences GAAP EPS of -$0.12 beats by $0.04

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ATAI Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/atai-stock-quote/">ATAI</a>) just reported results for the fourth quarter of 2023.<ul><li>ATAI Life Sciences reported earnings per share of -12 cents. This was above the analyst estimate for EPS of -16 cents.</li><li>The company reported revenue of $18,000.</li><li>This was 90.53% worse than the analyst estimate for revenue of $190,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/atai-stock-earnings-atai-life-sciences-for-q4-of-2023/">ATAI Stock Earnings: ATAI Life Sciences Beats EPS, Misses Revenue for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ATAI Stock Earnings: ATAI Life Sciences Beats EPS, Misses Revenue for Q4 2023

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.

March Recap: Largest Psychedelic Drug Stocks Up Another 5%

SLS, IBIO and ALDX are among premarket gainers

Atai Life Sciences upgraded at Maxim on Beckley investment

ACB, BRNS and EDUC among mid-day movers

The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.

Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD

The pharmaceutical industry is embracing AI to streamline drug discovery and researching the use of psychedelic compound-based ingredients for the treatment of, as yet, untreatable diseases.

The 10 Stocks In The Clinical-Stage BioTech Drug Stocks Index Are Down 4% YTD

A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and MTD, and their areas of focus.

Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week

ABCL

ABSI

BRNS

CDTX

COCH

EDUC

INVE

RLAY

RXRX

SDGR

Health Care

Press Releases

atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01

atai Life Sciences advances VLS-01 for treatment-resistant depression

Opinion

Thinking about buying stock in Lexicon Pharmaceuticals, Cassava Sciences, Clearside Biomedical, Lantern Pharma, or ATAI Life Sciences?

The Next Great Biotech Boom Has Arrived

atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights

Thinking about buying stock in Akebia Therapeutics, Mind Medicine, ATAI Life Sciences, Doma Holdings, or Iterum Therapeutics?

Momentum Stocks Alert: DYAI, KAVL, VTAK, NKLA, ATAI Demonstrate Financial Growth and Strategic Advancements

atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology

atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression